Saad, E. D., Squifflet, P., Burzykowski, T., Quinaux, E., Delaloge, S., Mavroudis, D., . . . Buyse, M. (2019). Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: A systematic review and meta-analysis. The lancet oncology, 20(3), 361-370. https://doi.org/10.1016/S1470-2045(18)30750-2
Citace podle Chicago (17th ed.)Saad, Everardo D., et al. "Disease-free Survival as a Surrogate for Overall Survival in Patients with HER2-positive, Early Breast Cancer in Trials of Adjuvant Trastuzumab for Up to 1 Year: A Systematic Review and Meta-analysis." The Lancet Oncology 20, no. 3 (2019): 361-370. https://doi.org/10.1016/S1470-2045(18)30750-2.
Citace podle MLA (9th ed.)Saad, Everardo D., et al. "Disease-free Survival as a Surrogate for Overall Survival in Patients with HER2-positive, Early Breast Cancer in Trials of Adjuvant Trastuzumab for Up to 1 Year: A Systematic Review and Meta-analysis." The Lancet Oncology, vol. 20, no. 3, 2019, pp. 361-370, https://doi.org/10.1016/S1470-2045(18)30750-2.